Prognostic values of micrornas in patients with Dukes' B and C colon cancer.

Résumé fourni par la source

3586 Background: Translational control mediated by noncoding microRNAs plays a key role in resistance to anticancer drug treatment. As a result, non-coding microRNAs hold great potential as new prognostic biomarkers. Previous studies from our laboratory have revealed that chemotherapeuric targets thymidylate synthase (TS) and dihydrofolate reductase (DHFR) were suppressed by miR-192 and miR-215 in colorectal cancer. miR-192 and miR-215 are candidate tumor suppressors due to the up-regulation of p53 and p21. The goal of this study is to find miRNAs as potential prognostic biomarkers in archival FFPE clinical samples of patients with stage II and III colon cancer. In this study, the expression of candidate miRNAs (let-7g, miR-21, miR-192, miR-215) was quantified from 15 stage II and 19 stage III colon specimens with up to 10 years clinical follow up information. Methods: Total RNAs were extracted from 34 paired normal and colon tumor specimens (stage II and III) using Trizol based approach. The levels of miRNAs were quantified using real time qRT-PCR expression analysis. Results: The expression of miR-192 (p = 0.0028) and miR-215 (p = 0.0001) was significantly decreased in colon tumors compared to normal adjacent mucosa. The expression of miR-21 was significantly elevated in colon tumor specimens (p = 0.0001). Kaplan-Meier survival analysis revealed that high levels of miR-215 expression (hazard ratio, 0.36; log rank test, p = 0.04) are closely associated with better patient's overall survival. Conclusions: miR-215 holds a great potential as prognostic biomarker in stage II and III colon cancer. No significant financial relationships to disclose.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.